Durvalumab

Extended indication	Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: - as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) - combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
Therapeutic value	No estimate possible yet
Registration phase	Registered

Product

Active substance	Durvalumab
Domain	Oncology
Reason of inclusion	Indication extension
Main indication	Cervical cancer
Extended indication	Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: - as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) - combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
Proprietary name	Imfinzi
Manufacturer	AstraZeneca
Mechanism of action	PD-1 / PD-L1 inhibitor
Route of administration	Intravenous
Budgetting framework	Intermural (MSZ)

Registration

ATMP	No
Submission date	2024
Expected Registration	September 2024
Orphan drug	No
Registration phase	Registered

Therapeutic value

Therapeutic value	No estimate possible yet

Expected patient volume per year

Patient volume	149 - 155 Market share is generally not included unless otherwise stated.
References	NKR (1); Advies - vergoed dostarlimab (Jemperli®) voor de behandeling van baarmoederkanker. Zorginstituut. 2024 (2).
Additional remarks	Jaarlijks worden ruim 2.000 nieuwe gevallen van endometriumcarcinoom gediagnosticeerd (1). Volgens de budget impactanalyse van de vergoeding van dostarlimab voor dezelfde indicatie als dit middel wordt een patiëntvolume van 149 tot 155 per jaar geschat (2).

Patient volume

149 - 155

Market share is generally not included unless otherwise stated.

References

NKR (1); Advies - vergoed dostarlimab (Jemperli®) voor de behandeling van baarmoederkanker. Zorginstituut. 2024 (2).

Additional remarks

Jaarlijks worden ruim 2.000 nieuwe gevallen van endometriumcarcinoom gediagnosticeerd (1). Volgens de budget impactanalyse van de vergoeding van dostarlimab voor dezelfde indicatie als dit middel wordt een patiëntvolume van 149 tot 155 per jaar geschat (2).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.